(Commercial Product)
Available Dosage Strengths
1.5 mg | 4 mg | 9 mg | 25 mg
Want to Prescribe?
Semaglutide (Wegovy® ) Tablet (Commercial Product by Novo Nordisk)
Semaglutide Injectable Description1-3
Semaglutide, a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA), is an incretin mimetic. Incretins are released from the gastrointestinal tract into the systemic circulation to improve glycemic control. The drug is used for the following indications:
References
Mechanism of Action 1-3
Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose levels. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.
Adverse Reactions1-3
Common
Contraindications & Precautions 1-3
Contraindications:
Precautions:
This information is for educational purposes only.
Wells Pharmacy Network distributes certain FDA-approved commercial products that are manufactured by third-party pharmaceutical companies. These products are not compounded or manufactured by Wells Pharmacy Network. Product availability at the time of dispensing may vary due to supply chain conditions.
This information is a summary. It may not cover all possible drug information about this product. For complete product information, refer to the manufacturer’s prescribing information and labeling. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.
